Provided and into the record to the conclusion of the hearing. I recognize myself for 5 minutes for Opening Statements. Let me find my Opening Statement here. I believe this hearing is long overdue. Suffering terrible inequalities. Unreliable access to the energy grid, little or no broadband connectivity, and reliable funds for the federal government and other systematic problems that created unnecessary hardship and turmoil and covid19 is exacerbating these long existing problems. One third of tribal members are at high risk of serious covid19 complications due to Underlying Health factors and Navajo Nation has seen higher infection rates than those in china at the peak of the pandemic. Despite this stark reality the impact of covid19 on tribal communities, weve seen the struggles of tribal communities and access to personal protective equipment and testing to protect against covid19. Is this pandemic redesign and covid19 cases continue to rise in many areas of the Country Access to p
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
Caption content and accuracy. Visit ncicap. Org] [captions Copyright National cable satellite corp. 2019] about 20 minutes left in this discussion. A reminder, you can find it online at cspan. Org wj. The house gaveling back in. We take you now to the floor. He house will resume proceedings on postponed questions at a later time. The hat purpose does gentleman from california seek recognition . Mr. Takano madam speaker, i suspend the house rules and pass h. R. 4920. The speaker pro tempore the clerk will report the title of the bill. The clerk h. R. 4920, a bill to amentitle 38, United States an , to provide for exception to certain Small Business contracting equirements applicable to the department of Veterans Affairs procurement of certain goods and Services Covered under the Ability One Program, and for other purposes. The speaker pro tempe pursuant to the rule, the california, mr. Takano, and the gentleman from will each bost, control 20 minutes. The chair recognizes the gentleman
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So